Au8, an experimental ALS therapy. CNM-Au8 has been associated with NfL reductions, a biomarker finding linked to longer ...
High-dose dazucorilant showed significant survival benefit in a Phase 2 ALS trial. It reduced mortality risk by up to 87% over two years for ALS patients. A pivotal Phase 3 trial for this ALS therapy ...
May is ALS Awareness Month, and in the U.S. and around the world, organizations are educating, sponsoring events, and encouraging the community to join them in taking action, providing financial ...
PIONEER-ALS, a clinical trial evaluating VTx-002 as a treatment for ALS, has been given a green light to launch study sites in three European nations. The therapy targets toxic TDP-43 protein clumps, ...
In the early, scary months after my late husband, Jeff, was diagnosed with ALS in the fall of 2018, I started to realize that I had no idea what we were up against. At almost 50 years old, I’d heard ...
ALS patients often experience weight loss, which is linked to poorer survival. Maintaining body weight after starting tube feeding is associated with longer survival in ALS. Weight stability after ...
Masitinib treatment for ALS led to 42% of patients in a clinical trial surviving five years, nearly double historical rates, an analysis found. About half of these long-term survivors maintained good ...
A large U.K. study found no clear link between long-term air pollution exposure and ALS risk. The researchers analyzed particulate matter and nitrogen oxides in more than 500,000 people over nearly a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results